{"id":"W2800681950","doi":"10.1200/jco.2013.31.15_suppl.tps8618","title":"A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Idelalisib; Bendamustine; Rituximab; Internal medicine; Follicular lymphoma; Lymphoma; Oncology; Ofatumumab; Clinical endpoint; Ibrutinib; Gastroenterology; Clinical trial; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002128154,0.00215477,0.003747152,0.0005137596,0.0005876138,0.00125385,0.001281039,0.002195717,0.007448338],"category_scores_gemma":[0.001631473,0.001197355,0.001315487,0.0005193868,0.001739543,0.00139112,0.0004548743,0.003986058,0.001591515],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009529504,"about_ca_system_score_gemma":0.00175899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009442529,"about_ca_topic_score_gemma":0.001991006,"domain_scores_codex":[0.9994063,0.0002789031,0.00003298899,0.0001309886,0.0000520489,0.00009872447],"domain_scores_gemma":[0.9989867,0.000218817,0.0002040466,0.00008394694,0.00006881299,0.0004376701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9684954,0.01720017,0.0004278607,0.0004294889,0.000472589,0.00004015382,0.00004136867,0.0002058197,0.003656792,0.00007334357,0.0006734866,0.008283591],"study_design_scores_gemma":[0.9354112,0.06303394,0.0006590963,0.00001226945,0.0001446258,0.00001910528,0.000009698535,0.0001868986,0.0001843411,0.00005529224,0.0002771304,0.000006440716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739422,0.003911096,0.00146522,0.000865231,0.0009785409,0.01383595,0.00173572,0.0002454103,0.003020703],"genre_scores_gemma":[0.970502,0.003009272,0.003081732,0.002017821,0.0007495549,0.01475749,0.001548241,0.0000413645,0.004292485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007448338,"threshold_uncertainty_score":0.02491719,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09848421511876561,"score_gpt":0.4642473764283994,"score_spread":0.3657631613096338,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}